据证券之星公开数据整理，近期大博医疗（002901）发布2025年中报。截至本报告期末，公司营业总收 入12.1亿元，同比上升25.55%，归母净利润2.44亿元，同比上升76.69%。按单季度数据看，第二季度营 业总收入6.6亿元，同比上升22.96%，第二季度归母净利润1.41亿元，同比上升84.47%。本报告期大博 医疗盈利能力上升，毛利率同比增幅6.21%，净利率同比增幅36.92%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率71.01%，同比增6.21%，净利率21.42%，同比增 36.92%，销售费用、管理费用、财务费用总计3.78亿元，三费占营收比31.23%，同比减13.55%，每股净 资产7.59元，同比增1.69%，每股经营性现金流0.63元，同比增96.3%，每股收益0.6元，同比增79.9% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 9.64Z | 12.1亿 | 25.55% | | 归母净利润(元) | 1.38 Z | 2.44亿 | 76.69% | | 扣非净利润 ...

Group 1: Business Impact and Market Trends - The company's market share has been increasing post-collective procurement, but the profit margin for 2024 is still lower than before the policy implementation [1] - Since 2021, the orthopedic consumables have achieved full national procurement coverage across four major product categories: joints, spine, trauma, and sports medicine, leading to increased industry concentration [2] Group 2: Core Competitiveness - The company focuses on innovation and R&D as a core driver, increasing investment to meet clinical needs with high-quality products, which helps to enhance market share [2] - Technical services play a crucial role, with regular training for distributors to ensure high product and clinical compatibility [2] - The company leverages economies of scale to gradually reduce costs [2] Group 3: R&D Investment - R&D investment has increased due to a decline in overall revenue post-collective procurement, while maintaining previous investment levels [3] - The company invests in various orthopedic fields, including trauma, spine, joints, and sports medicine, as well as non-orthopedic areas like dental and neurosurgery [3] Group 4: Capital Expenditure Plans - The company completed its refinancing project by the end of 2024 and has no large-scale capital expenditure plans currently, having passed the peak of construction [4] Group 5: Robotics and International Market - The knee joint robot has begun clinical applications, with ongoing efforts to register other orthopedic robots [5] - The company exported products to over 60 countries, with overseas revenue of approximately 217 million yuan in 2024, accounting for 10.16% of total revenue [7] - The company is open to acquisitions to enhance its international market competitiveness [7] Group 6: Future Planning - The company aims to achieve higher market shares in trauma, spine, joints, and sports medicine, targeting top positions in each field [8] - Plans to strengthen market expansion in countries along the "Belt and Road" initiative and in Europe and the United States [8] Group 7: Infrastructure and Logistics - The company has established a logistics network across most prefecture-level cities in China, enhancing its core competitiveness [9] - Investment in logistics and digital platforms will continue, although the pace is slowing down as the construction phase concludes [9]